These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 29572471)

  • 1. BAFF-neutralizing interaction of belimumab related to its therapeutic efficacy for treating systemic lupus erythematosus.
    Shin W; Lee HT; Lim H; Lee SH; Son JY; Lee JU; Yoo KY; Ryu SE; Rhie J; Lee JY; Heo YS
    Nat Commun; 2018 Mar; 9(1):1200. PubMed ID: 29572471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of Membrane-Bound BAFF by the Anti-BAFF Antibody Belimumab.
    Kowalczyk-Quintas C; Chevalley D; Willen L; Jandus C; Vigolo M; Schneider P
    Front Immunol; 2018; 9():2698. PubMed ID: 30524439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic targeting of the BAFF/APRIL axis in systemic lupus erythematosus.
    Stohl W
    Expert Opin Ther Targets; 2014 Apr; 18(4):473-89. PubMed ID: 24521424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men.
    Schwarting A; Relle M; Meineck M; Föhr B; Triantafyllias K; Weinmann A; Roth W; Weinmann-Menke J
    Lupus; 2018 Feb; 27(2):243-256. PubMed ID: 28659046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Unexpected Potency Differences between B-Cell-Activating Factor (BAFF) Antagonist Antibodies against Various Forms of BAFF: Trimer, 60-Mer, and Membrane-Bound.
    Nicoletti AM; Kenny CH; Khalil AM; Pan Q; Ralph KL; Ritchie J; Venkataramani S; Presky DH; DeWire SM; Brodeur SR
    J Pharmacol Exp Ther; 2016 Oct; 359(1):37-44. PubMed ID: 27440419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Belimumab therapy in systemic lupus erythematosus.
    Zouali M; Uy EA
    BioDrugs; 2013 Jun; 27(3):225-35. PubMed ID: 23568179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Function, occurrence and inhibition of different forms of BAFF.
    Eslami M; Schneider P
    Curr Opin Immunol; 2021 Aug; 71():75-80. PubMed ID: 34182216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment with belimumab restores B cell subsets and their expression of B cell activating factor receptor in patients with primary Sjogren's syndrome.
    Pontarini E; Fabris M; Quartuccio L; Cappeletti M; Calcaterra F; Roberto A; Curcio F; Mavilio D; Della Bella S; De Vita S
    Rheumatology (Oxford); 2015 Aug; 54(8):1429-34. PubMed ID: 25740829
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and emerging treatment options for ANCA-associated vasculitis: potential role of belimumab and other BAFF/APRIL targeting agents.
    Lenert A; Lenert P
    Drug Des Devel Ther; 2015; 9():333-47. PubMed ID: 25609919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases.
    Samy E; Wax S; Huard B; Hess H; Schneider P
    Int Rev Immunol; 2017 Jan; 36(1):3-19. PubMed ID: 28215100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. B cell alterations during BAFF inhibition with belimumab in SLE.
    Ramsköld D; Parodis I; Lakshmikanth T; Sippl N; Khademi M; Chen Y; Zickert A; Mikeš J; Achour A; Amara K; Piehl F; Brodin P; Gunnarsson I; Malmström V
    EBioMedicine; 2019 Feb; 40():517-527. PubMed ID: 30593436
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Belimumab for the treatment of systemic lupus erythematosus.
    Jordan N; D'Cruz DP
    Expert Rev Clin Immunol; 2015 Feb; 11(2):195-204. PubMed ID: 25543845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neutralization of (NK-cell-derived) B-cell activating factor by Belimumab restores sensitivity of chronic lymphoid leukemia cells to direct and Rituximab-induced NK lysis.
    Wild J; Schmiedel BJ; Maurer A; Raab S; Prokop L; Stevanović S; Dörfel D; Schneider P; Salih HR
    Leukemia; 2015 Aug; 29(8):1676-83. PubMed ID: 25710310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Belimumab alters transitional B-cell subset proportions in patients with stable systemic lupus erythematosus.
    Benitez A; Torralba K; Ngo M; Salto LM; Choi KS; De Vera ME; Payne KJ
    Lupus; 2019 Oct; 28(11):1337-1343. PubMed ID: 31423896
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date.
    Lenert A; Niewold TB; Lenert P
    Drug Des Devel Ther; 2017; 11():747-757. PubMed ID: 28331294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy, pharmacokinetic and pharmacodynamic profile of belimumab for systemic lupus erythematosus.
    Jordan NP; D'Cruz DP
    Expert Opin Drug Metab Toxicol; 2015; 11(10):1635-45. PubMed ID: 26327145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BAFF inhibition in SLE-Is tolerance restored?
    Jackson SW; Davidson A
    Immunol Rev; 2019 Nov; 292(1):102-119. PubMed ID: 31562657
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 'That Obscure Object of Desire': in systemic lupus erythematosus B-cell activating factor/B-lymphocyte stimulator is targeted both by the immune system and by physicians.
    Sanchez-Niño MD; Ortiz A
    Nephrol Dial Transplant; 2015 Mar; 30(3):394-400. PubMed ID: 24914092
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The rationale for BAFF inhibition in systemic lupus erythematosus.
    Davidson A
    Curr Rheumatol Rep; 2012 Aug; 14(4):295-302. PubMed ID: 22535567
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deleting the BAFF receptor TACI protects against systemic lupus erythematosus without extensive reduction of B cell numbers.
    Figgett WA; Deliyanti D; Fairfax KA; Quah PS; Wilkinson-Berka JL; Mackay F
    J Autoimmun; 2015 Jul; 61():9-16. PubMed ID: 26027434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.